The Association Between Location of BRCA Mutation and Efficacy of PARP Inhibitor as a Frontline Maintenance Therapy in Advanced Epithelial Ovarian Cancer
Frontline PARP inhibitor maintenance therapy demonstrated a significant PFS benefit in patients with <i>BRCA1</i>/<i>2</i> mutations, with particularly pronounced benefits for those with mutations located in the DBD of <i>BRCA1</i> and <i>BRCA2</i>. However, the benefit was less evident for patients with <i>BRCA1</i> mutations located in the BRCT domain.
Authors
- Eunji Nam (ORCID: https://orcid.org/0000-0002-2967-2113)
- Se Ik Kim (ORCID: https://orcid.org/0000-0002-9790-6735)
- Sang Wun Kim (ORCID: https://orcid.org/0000-0002-8342-8701)
- Eun Taeg Kim (ORCID: https://orcid.org/0000-0002-2754-2657)
- Hyeong In Ha (ORCID: https://orcid.org/0000-0002-7045-7976)
- Young Tae Kim (ORCID: https://orcid.org/0000-0002-7347-1052)
- Jung‐Yun Lee (ORCID: https://orcid.org/0000-0001-7948-1350)
- Yong Jae Lee (ORCID: https://orcid.org/0000-0003-0297-3116)
- Sunghoon Kim (ORCID: https://orcid.org/0000-0002-1645-7473)
- Ji Hyun Kim (ORCID: https://orcid.org/0000-0002-4746-5572)
- Dong-Eun Lee (ORCID: https://orcid.org/0000-0001-8525-7494)
- Sang-Yoon Park (ORCID: https://orcid.org/0000-0001-7624-3373)
Institutions
- Seoul National University (KR)
- Yonsei University (KR)
- Severance Hospital (KR)
- National Cancer Center (KR)
- Kosin University (KR)
Publication Details
- Journal
- Cancers
- Published
- 2025-02-23
- DOI
- https://doi.org/10.3390/cancers17050756
- Citations
- 6
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 6.27